Screener
Immunome IMNM EPS (Basic)
EPS (Basic) at other companies
Other financials
Where this comes from
Reported directly by Immunome in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The source filing: Immunome’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:10 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219425
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss from operations | (59,331) | (44,636) |
| Interest income | 5,492 | 2,996 |
| Net loss | $(53,839) | $(41,640) |
| Net loss per share, basic and diluted | $(0.48) | $(0.52) |
| Weighted-average shares outstanding, basic and diluted | 113,136,836 | 79,410,354 |
| Comprehensive loss: | ||
| Net loss | $(53,839) | $(41,640) |
| Unrealized loss on marketable securities | — | (60) |
Item 1. Financial Statements.
FAQ
- What is Immunome's EPS (basic)?
- Immunome (IMNM) reported EPS (basic) of -$0.48 in Q1 2026.
- How has Immunome's EPS (basic) changed year-over-year?
- Immunome's EPS (basic) increased by 7.7% year-over-year, from -$0.52 to -$0.48.
- What is the long-term trend for Immunome's EPS (basic)?
- Over 4 years (2021 to 2025), Immunome's EPS (basic) has grown at a 3.2% compound annual growth rate (CAGR), from -$2.13 to -$2.42.
- What does EPS (basic) mean?
- Net income available to common shareholders divided by the weighted-average number of common shares outstanding during the period. Does not account for dilutive securities.
Ask your AI about Immunome's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude